Notizia - Recent Pharma, Healthcare and Biotech Happenings

recent-pharma-news-and-updates-for-gilead-roche-celleron-f2g

Gilead’s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche’s cancer drug

Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead’s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Black, Latinx, and Native Americans. The researchers cite data in the New England Journal of Medicine, showing Black Americans account for a disproportionate number of COVID-19 cases in the U.S. In Alabama, Black or African American people report 27% of the population but account for 43% of cases. Hispanic or Latino people are also over-represented in COVID-...

Explore More...

Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings

Letter for AstraZeneca; Patheon on API plant; Sanofi, Regeneron’s Dupixent; Cerulean Pharma and Daré Bioscience enter into deal; Lilly on price hikes

Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns

GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss

ALCMI, ALCF and Scancell partner; Sun unloads Ohm Labs plants; Takeda and Ovid join; Guardant and MD Anderson collaborate; Glooko and Ascensia integrate

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Gilead’s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche’s cancer drug

Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings

Letter for AstraZeneca; Patheon on API plant; Sanofi, Regeneron’s Dupixent; Cerulean Pharma and Daré Bioscience enter into deal; Lilly on price hikes

Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns

GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss

Pfizer faces patent loss; Allergan over generics probe; Sun Pharma rallies

Business Cocktail

NPPA slams; Japan Joins Trump; PCI Pharma Announces Expansion; Merck opens plant; Mylan and Biocon win

Clinigen and Eisai team up; Sanofi, Lonza enter; Fidia to acquire; J&J completes acquisition

More Views & Analysis

Prosecutors rope Pfizer; Pharma groups to FDA; Regeneron simulates; Otsuka & Lundbeck revive;Philidor execs plead

PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch

USFDA warns; Vit B3 prevents glaucoma; Zydus Cadila receives nod; U.S. experts soften on DNA editing

Reckitt Acquired Mead Johnson; LabCorp’s acquisition; Ferring collaborates; J&J Licenses

SEC scrutinizes; Acacia meets endpoint; Axovant’s dementia drug; Novartis expands; Aurobindo responds

AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires; Renova takes over Rights

FDA approves; Sun Pharma Recalls; Mezzion filed; Sanofi’s antibody to treat

ALCMI, ALCF and Scancell partner; Sun unloads Ohm Labs plants; Takeda and Ovid join; Guardant and MD Anderson collaborate; Glooko and Ascensia integrate

Subscribe to our Updates

Daily

Weekly

Monthly